Risks and effectiveness of compounded bioidentical hormone therapy: A case series

Journal of Women's Health

Volumn 23, Issue 8, 2014, Pages 642-648

  Davis, Ruth ^a   Batur, Pelin ^a,b   Thacker, Holly L ^a,b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRIOL; ESTRONE; PROGESTERONE; BIOSIMILAR AGENT;

ADULT; ARTICLE; BIOIDENTICAL HORMONE THERAPY; BREAST CANCER; CASE REPORT; ENDOMETRIUM CANCER; FEMALE; FOOD AND DRUG ADMINISTRATION; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; PATIENT REFERRAL; PRIORITY JOURNAL; AGED; DRUG EFFECTS; DRUG FORMULATION; ENDOMETRIAL NEOPLASMS; ESTROGEN THERAPY; MENOPAUSE; MIDDLE AGED; PATHOLOGY; THERAPEUTIC EQUIVALENCE; TREATMENT OUTCOME; UNITED STATES; WOMEN'S HEALTH;

AGED; BIOSIMILAR PHARMACEUTICALS; DRUG COMPOUNDING; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTRIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PROGESTERONE; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WOMEN'S HEALTH;

EID: 84905982593     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2014.4770     Document Type: Article

References (31)

1. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 2004;291:47-53.
2. Rossouw JE, Anderson GL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-333.
3. Hing E, Brett KM. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol 2006;108:33-40.
4. Pattimakiel L, Thacker HL. Bioidentical hormone therapy: Clarifiying the misconceptions. Cleve Clin J Med 2011;78: 829-836.
5. Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc 2011;86:673-680.
6. US Food and Drug Administration (FDA). Compounded Menopausal hormone therapy questions and answers. Available at www.fda.gov/Drugs/ GuidanceComplianceRegulatory Information/PharmacyCompounding/ucm183088.htm Accessed January 18, 2014.
7. Sood R, Warndahl RA, et al. Bioidentical compounded hormones: A pharmacokinetic evaluation in a randomized clinical trial. Maturitas 2013;74:375-382.
8. Reginster JY, Sarlet N, et al. Minimal levels of serum es-tradiol prevent postmenopausal bone loss. Calcif Tissue Int 1992;51:340-343.
9. Ettinger B, Pressman A, et al. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: The Study of Osteoporotic Fractures. J Clin Endocrinol Metab 1998;83:2239-2243.
10. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; CD002978. DOI: 10.1002/14651858.CD002978.pub2.
11. Ruiz AD, Daniels KR, Braner JC, Carson JJ, Frei CR. Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study. BME Womens Health 2011;11:27.
12. Stephenson K, Neuenschwander PF, Kurdowska AK. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. Int J Pharm Compd 2013;17:74-85.
13. Eden JA, Hacker NF, Fortune M. Three cases of endome-trial cancer associated with "bioidentical" hormone replacement therapy. Med J Aust 2007;187:244-245.
14. Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee. Committee opinion No. 532: Compounded bioidentical menopausal hormone therapy. Obstet Gynecol 2012;120: 411-415.
15. Archer DF. Neoplasia of the female reproductive tract. Effects of hormone therapy. Endocrine 2004;24:259-263.
16. Gillet JY, Andre G, et al. Induction of amenorrhea during hormone replacement therapy: Optimal micronized progesterone dose. A multicenter study. Maturitas 1994;19: 103-115.
17. US Food and Drug Administration (FDA). Report: Limited FDA survey of compounded drug products. Available at www.fda.gov/Drugs/ GuidanceComplianceRegulatory Information/PharmacyCompounding/ucm155725.htm Accessed January 18, 2014.
18. Fugh-Berman A, Bythrow J. Bioidentical hormones for menopausal hormone therapy: Variation on a theme. JGIM 2007;22:1030-1034.
19. Whelan AM, Jurgens TM, Trinacty M. Bioidentical progesterone cream for menopause-related vasomotor symptoms: Is it effective? Ann Pharmacother 2013;47:112-116.
20. Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in the long-term tissue culture. Cancer Res 1977; 37:1901-1907.
21. Fournier A, Berrino F, Clavel-Chapelon, F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 2008;107:307-308.
22. Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lig-niéres B. Influences of percutaneous administration of es-tradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785-791.
23. Foidart JM, Colin C, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-969.
24. Simon JA. What if the Women's Health Initiative has used transdermal estradiol and oral progesterone instead? Menopause 2014;21:1-15.
25. Harvey JA, Pinkerton JV, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/con-jugated estrogens. Menopause 2013;20:138-145.
26. US Food and Drug Administration (FDA). FDA takes action against compounded menopause hormone therapy drugs. Available at www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2008/ucm116832.htm Accessed January 18, 2014.
27. Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee (ACOG). ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstet Gynecol 2014;123: 202-216.
28. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: An Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1-s66.
29. Sturdee DW, Pines A. International Menopause Society Writing Group, et al. Updated IMS recommendations on postmenopausall hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302-320
30. Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee.
31. Committee opinion No. 556: Postmenopause estrogen therapy: Route of administration and risk of venous thrombo-embolism. Obstet Gynecol 2013;121:891-896.